After senolysis, concurrent CD38i+precursor residual ΔNAD fails to exceed better sequential
STATUS_LABEL: NEGATIVE
polarity: negative swarm_id: L13 card_sha256: 8ea25a3ba1b8c1f939f79f843549d746140a1ea0462dbaad379543596ac55c8f risk_class: research-discussion note: PASS_NEGATIVE — shipped as discussion (not claim/hypothesis). Soft-complete concurrent∩sequential∩senolytic empty/non-match; matched concurrent-vs-sequential-best residual ΔNAD H2H remains UNKNOWN. L9≠this; L12 left concurrent open; L5–L12 ≠ proof.
Claim
After documented senescent-cell / SASP clearance, residual tissue ΔNAD from concurrent CD38-inhibitor + NAD-precursor at matched total exposure fails to exceed residual tissue ΔNAD from the better of the two sequential order arms (CD38i→precursor vs precursor→CD38i) — pre-registered residual_concurrent ≤ sequential_best + surplus_margin (assumption-kill of “always stack both at once after clearance”).
Why it matters
Longevity stacks often co-dose CD38i with NAD precursors after senolysis, assuming concurrent residual ΔNAD beats any sequential schedule. Distinct from L9 (stack surplus vs max(single) ≠ concurrent vs sequential-best), L12 (order asymmetry A≠B left concurrent vs sequential-best OPEN), L5/L6 ranking, L10/L11 duals. Soft-claims: discussion — soft-complete concurrent∩sequential∩senolytic empty / non-match; matched concurrent-vs-sequential-best H2H remains UNKNOWN; L9≠this; L12 left concurrent open; L5–L12 ≠ proof. Co-treatment without senolysis order ≠ this panel; 78c monotherapy ≠ concurrent vs sequential readout.
Mechanism sketch
Subtract-before-add: clear SASP-driven CD38+ macrophage load first, then run three matched-exposure arms — concurrent CD38i+precursor vs sequential A (CD38i→precursor) vs sequential B (precursor→CD38i) — and score residual tissue ΔNAD against sequential_best = max(A, B). CD38 gates age NAD decline and NMN fate; SASP induces CD38-high macrophages that drain tissue NAD; senescent/SASP ablation lowers CD38 and partially restores NAD via an NMN-dependent ecto-block route; 78c-class CD38i improves aged-mouse healthspan as monotherapy (not a concurrent-vs-sequential panel). Incomplete clearance / residual CD38+ load can interact with schedule (concurrent vs sequential); that interaction is predicted, not measured. Adjacent CD38i+NR co-treatment without senolysis order is not this H2H.
Prior art
- PMID 27304511 / DOI 10.1016/j.cmet.2016.05.006 / PMC4911708 — age NAD↓ requires CD38; CD38 gates NMN fate in vivo (Camacho-Pereira 2016) — CD38–NAD / NMN-gating prior for residual assays.
- PMID 33199924 / DOI 10.1038/s42255-020-00305-3 / PMC7908681 — SASP induces CD38-high macrophages that reduce tissue NAD (Covarrubias 2020) — subtract-before-add / incomplete-clearance motivation; not concurrent-vs-sequential panel.
- PMID 33199925 / DOI 10.1038/s42255-020-00298-z / PMC8752031 — senescent/SASP ablation ↓CD38 and partially restores NAD; ecto-CD38 block raises NAD via NMN-dependent process (Chini 2020) — post-clearance baseline prior, not concurrent vs sequential-best H2H.
- PMID 35263032 / DOI 10.1111/acel.13589 / PMC9009115 — CD38i 78c increases lifespan/healthspan in chronological aging (Tarragó 2022) — monotherapy tool prior, not concurrent vs sequential panel after senolysis.
Baseline claimed
After senolysis, concurrent CD38i+precursor residual tissue ΔNAD fails to exceed the better of the two sequential order arms at matched total exposure — or L9 stack surplus / L12 order asymmetry / L5–L12 ranking-dual-stack cards already settle concurrent vs sequential-best.
Baseline measured
CD38 gates age NAD / NMN fate LITERATURE (PMID 27304511). SASP→CD38+ macrophages→tissue NAD↓ LITERATURE (PMID 33199924). Clearance ↓CD38 + partial NAD rebound; ecto-block NMN-dependent LITERATURE (PMID 33199925). 78c aged-mouse benefit LITERATURE monotherapy (PMID 35263032). Matched H2H concurrent vs sequential-best residual ΔNAD after senolysis UNKNOWN (soft-complete concurrent∩sequential∩senolytic = 0; adjacent co-treatment PMID 33871064 / review 36678315 / doxorubicin 78c–NMN 41021886 ≠ concurrent-vs-sequential-best H2H). Concurrent-fails-to-exceed PREDICTION. L9 ≠ this; L12 left concurrent open; L5–L12 ≠ proof — ranking ≠ schedule; stack surplus ≠ concurrent vs sequential-best; order asymmetry ≠ concurrent residual vs sequential-best; co-treatment ≠ this panel.
Actionable limitations
- Do not treat L5–L12 as proving L13 — ranking / stack surplus / duals / sequential order asymmetry never ran matched concurrent vs sequential-best residual ΔNAD after clearance; soft-complete empty ≠ demonstrated concurrent-failure.
- Co-treatment ≠ concurrent-vs-sequential-best — concurrent CD38i + NR without senolysis order (e.g. PMID 33871064) or synergistic-stack reviews (PMID 36678315) do not report concurrent vs max(sequential A, B) residual ΔNAD after matched senolytic/SASP run-in.
- L9 ≠ L13 (stack surplus ≠ concurrent vs sequential-best); L12 ≠ L13 (order asymmetry left concurrent OPEN); incomplete clearance / target-load may interact with schedule; Chini clearance/ecto-block and 78c monotherapy are not this panel; no dosing.
Method
propose-assay
Prediction variables
| name | kind | assay | threshold |
|---|---|---|---|
| CD38_gates_age_NAD_and_NMN | LITERATURE | Aging NAD metabolome vs CD38; NMN fate (Camacho-Pereira 2016) | age NAD↓ requires CD38; gates NMN fate (PMID 27304511) |
| SASP_CD38_macrophage_NAD_drain | LITERATURE | Senescent/SASP-conditioned macrophage CD38 and tissue NAD (Covarrubias 2020) | SASP induces CD38-high macrophages that reduce tissue NAD (PMID 33199924) |
| clearance_CD38_drop_NAD_rebound_ecto_NMN_dependent | LITERATURE | Senescent/SASP ablation → CD38↓ + partial NAD↑; ecto-CD38 block NAD boost (Chini 2020) | CD38↓ with partial NAD recovery; ecto-block raises NAD via NMN-dependent route (PMID 33199925) — clearance prior, not concurrent-vs-sequential panel |
| CD38i_78c_aged_mouse_monotherapy | LITERATURE | Chronological-aging 78c survival/healthspan (Tarragó 2022) | lifespan/healthspan class effect as monotherapy — not concurrent vs sequential panel after senolysis (PMID 35263032) |
| matched_concurrent_vs_sequential_best_H2H_panel | UNKNOWN | Matched senolytic/SASP run-in → concurrent CD38i+NAD-precursor vs sequential A (CD38i→precursor) vs sequential B (precursor→CD38i) at matched total exposure; residual tissue ΔNAD ± CD38 activity; prefer cell / SASP-conditioned macrophage panel before animal | dedicated concurrent-vs-sequential-best residual panel not found (soft-complete concurrent∩sequential∩senolytic = 0; adjacent co-treatment/review/doxorubicin non-matches) — UNKNOWN |
| concurrent_fails_to_exceed_sequential_best_residual_deltaNAD | PREDICTION | Pre-registered aged tissue or SASP-conditioned cell system; verified clearance → concurrent vs seq A vs seq B at matched total exposure; residual ΔNAD readout (nmol NAD+/mg protein or fold vs post-clearance baseline) | residual_concurrent ≤ sequential_best + pre-registered surplus_margin (tissue ΔNAD units; α/N pre-specified) — concurrent fails to exceed better sequential; do not invent observed Δ or dosing |
| competing_concurrent_exceeds_or_incomplete_clearance | PREDICTION | Same design; competing outcomes if residual_concurrent exceeds sequential_best outside surplus_margin when clearance is verified — or if apparent concurrent-failure is only incomplete-clearance / exposure-mismatch / assay-definition artifact | concurrent-exceeds / incomplete-clearance / exposure-mismatch / assay-definition failure allowed as pre-registered competing outcomes (inconclusive_if ≠ refute_if) |
Ablate
- remove matched H2H concurrent CD38i+precursor vs sequential A/B residual ΔNAD arms after documented senolysis / SASP clearance at matched total exposure: Without the concurrent-vs-sequential-best residual readout, solo-lever LITERATURE and co-treatment cannot show concurrent failure to exceed sequential-best.
- remove documented clearance run-in with CD38↓ / partial NAD rebound verification before concurrent and both sequential arms: Without subtract-first confirmation, the card collapses into co-treatment-without-clearance and loses the post-senolysis subtract-before-add frame.
- remove L5–L12≠proof + L9≠this + L12-left-concurrent-open + co-treatment≠schedule-H2H + soft-complete-empty≠failure discipline: Treating L5–L12 ranking/duals/stack/order, concurrent CD38i+NR without senolysis order, or empty PubMed as already deciding concurrent-failure would invent an H2H result left UNKNOWN.
Refute if
On the pre-registered concurrent-vs-sequential-best residual panel after verified clearance, residual_concurrent exceeds sequential_best = max(residual_CD38i_then_precursor, residual_precursor_then_CD38i) outside the pre-registered surplus_margin (concurrent DOES beat better sequential), when CD38↓ is verified — especially under incomplete clearance, exposure mismatch, or when apparent concurrent-failure is only an assay-definition artifact under the pre-registered residual definitions.
Ask a human
Lock tissue or cell system (prefer SASP-conditioned macrophage / WAT or liver explant before whole-animal), clearance verification (CD38 activity + SC/SASP marker), matched total exposure for concurrent CD38i (78c-class) + NAD precursor (NMN/NR-class) vs sequential arms A/B, and residual ΔNAD definition (nmol/mg or fold vs post-clearance baseline) before claiming concurrent fails to exceed sequential-best after senolysis; do not treat L5–L12 as proof; L9≠this; L12 left concurrent open; co-treatment ≠ this panel; no dosing.
Cheap IP
kill_cost_tier=2 · time_to_refute=6w · ip_class=subtract-before-add · vault_hold=no
Execution
execution_status=NOT_RUN · fto_status=UNKNOWN · related_prior=L5–L12 (ranking/duals/stack surplus/order asymmetry ≠ concurrent vs sequential-best residual proof; L9≠this; L12 left concurrent open)